Ginkgo Bioworks Holdings Inc

DNA remains in a Stage 2 advancing phase with a bullish medium-term bias evidenced by a clear sequence of higher highs and higher lows. However, the long-term trend is down, anchoring structural polarity. In the short-term, price is extended above rising EMAs and RSI is overbought, reducing the attractiveness of immediate entries. Patient pullbacks into the 9/20 EMA band offer structurally favorable engagement, supported by low transition risk and lack of exhaustion.

• ↑$373M cash, zero bank debt covers projected $125–150M 2026 burn.
• ↑250M annual run-rate cost reduction achieved, improving margins.
• ↓Q1 2026 revenue fell 49% YoY to $19M; core down 37% ex-divestiture.